Renal Cell Carcimona Cancer Drug Futures

Report Summary

AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Renal Cell Carcinoma Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective annual price of £1,495/US$2,615/€1,865

• 24/7 web access
• Quarterly updated pdf reports
• Single cost-effective price
• All updates including any new drugs added during your license period
• Related news
• Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system

The number of renal cell carcinoma (RCC) patients.

by value, in the US, Europe and Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to approximately 832,000 in 2015). Approximately 18% of the RCC patient population currently receives drug therapy but, by 2015, this percentage is expected to grow reflecting an increase in the number of treatment options, improvements in drug efficacy and the use of drug therapy earlier in the course of the disease.

The total RCC sales for branded products will increase substantially from almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%. Sales will be driven by the new targeted therapies which will account for sales of around US$6.1 billion in 2015,

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Renal Cell Carcinoma Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug’s progress and stay abreast of developments
Understand the drug’s novelty and mode of action
Evaluate the strength of the company developing/producing the drug
Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
Know the launch timeframe for new products or indications
Be aware of promising mid-stage development candidates
Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

• Novelty/rationale for mechanism of action
• Current status
• Proof of concept/clinical data
• Development risks
• Company expertise
• Competition within the market-place
• Sales forecast (for key late-stage and launched products)
• Competitor ratio analysis score
• Clinical trial results

OVER 35 RCC DRUGS INCLUDED:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
Aldesleukin
Bevacizumab
Everolimus
Human lymphoblastoid interferon [IFN] alpha-N1
Interferon alpha-2a
Pazopanib
Sorafenib
Sunitinib malate
Temsirolimus
Vitespen
 Phase III
Axitinib
Girentuximab
Naptumomab
Tivozanib
 Phase II
AGS-003
AS1411
BIBF 1120
Foretinib
IMA901
Interleukin-21
L19
Linifanib
Panobinostat
Perifosine
Ramucirumab
Regorafenib
Talactoferrin alpha
 Phase I/II
Dovitinib
IMP321
OncoVAX

Dicontinued/Suspended/Withdrawn
ABT-510
ABT-751
Archexin
SAR109659
IMO-2055

CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

For further information on the products covered, discounts, distribution or a demonstration, please click on the link for Mark Hamson.

CANCER SECTORS COVERED IN THE DRUG FUTURE SERVICE

Breast
Lung
Colorectal
Renal Cell Carcinoma
Prostate
Blood (coming soon)

Table of Contents

OVERVIEW . 1

PHASE I. 3

TREMELIMUMAB  3
Mode of Action . 3
Current Status  3
Proof of Concept/Clinical Data  3
Development Risks . 3
Company Expertise . 3

PHASE I/II . 4
DOVITINIB  4
Mode of Action . 4
Current Status  5
Proof of Concept/Clinical Data  5
Development Risks . 5
Company Expertise . 5
IMP321  6
Mode of Action . 6
Current Status  6
Proof of Concept/Clinical Data  6
Company Expertise . 7
Competition within the Market-place  7
Competitor Ratio Analysis  7

ONCOVAX  8
Mode of Action . 8
Current Status  8
Proof of Concept/Clinical Data  8
Development Risks . 9
Company Expertise . 9
Competition within the Market-place 10
Competitor Ratio Analysis 11
Forecast .12
PHASE II  13
AGS-003 13
Mode of Action 13
Current Status 13
Proof of Concept/Clinical Data 13
Development Risks 14
Company Expertise 14
Competition within the Market-place 14
Competitor Ratio Analysis 14

RCC DRUG FUTURES
Clinical Trial Results .15
AS1411 . 16
Mode of Action 16
Current Status 17
Proof of Concept/Clinical Data 17
Development Risks 17
Company Expertise 17
Competition within the Market-place 18
BIBF 1120 . 19
Mode of Action 19
Current Status 19
Proof of Concept/Clinical Data 20
Development Risks 20
Company Expertise 20
Competition Within the Market-place .21
Competitor Ratio Analysis 21
Forecast .21
Clinical Trial Results .22

FORETINIB . 24
Mode of Action 24
Current Status 24
Proof of Concept/Clinical Data 24
Development Risks 25
Company Expertise 25
Competition within the Market-place 25
Competitor Ratio Analysis25
IMA901 . 26
Mode of Action 26
Current Status 26
Proof of Concept/Clinical Data 27
Development Risks 27
Company Expertise 27
Competition within the Market-place 27
Competitor Ratio Analysis 28

INTERLEUKIN-21 29
Mode of Action 29
Current Status 30
Proof of Concept/Clinical Data 30
Development Risks 30
Company Expertise 31
Competition within the Market-place 31
Competitor Ratio Analysis 31
Clinical Trial Results .32
L19 . 34
Mode of Action 34
Current Status 34

LINIFANIB  35
Mode of Action 35
Current Status 35
Proof of Concept/Clinical Data 35
Development Risks 36
Company Expertise 36
Competition within the Market-place 36
Competitor Ratio Analysis 37

PANOBINOSTAT . 38
Mode of Action 38
Current Status 39
Proof of Concept/Clinical Data 39
Development Risks 39
Company Expertise 39
Competition Within the Market-place .39
Competitor Ratio Analysis 40
Forecast .40
Clinical Trial Results .41

PERIFOSINE 42
Mode of Action 42
Current Status 43
Proof of Concept/Clinical Data 43
Development/Commercialisation Risks 44
Company Expertise 44
Competition within the Market-place 45
Competitor Ratio Analysis 45
Forecast .45

RAMUCIRUMAB  46
Mode of Action 46
Current Status 46
Proof of Concept/Clinical Data 46
Development Risks 46
Company Expertise 47
Competition within the Market-place 47
Competitor Ratio Analysis 47
Forecast .48

REGORAFENIB . 49
Mode of Action 49
Current Status 49
Proof of Concept/Clinical Data 49
Development Risks 50
Company Expertise 50
Competition within the Market-place 50
Competitor Ratio Analysis 50
Clinical Trial Results .51

TALACTOFERRIN ALPHA 52
Mode of Action 52
Current Status 53
Proof of Concept/Clinical Data 53
Development Risks 54
Company Expertise 54
Competition within the Market-place 54
Competitor Ratio Analysis 55
Clinical Trial Results .55

PHASE III  57

AXITINIB 57
Mode of Action 57
Current Status 57
Proof of Concept/Clinical Data 58
Development Risks 58
Company Expertise 59
Competition within the Market-place 59
Competitor Ratio Analysis 60
Forecast .60
Clinical Trial Results .62

GIRENTUXIMAB  64
Mode of Action 64
Current Status 64
Proof of Concept/Clinical Data 65
Development Risks 65
Company Expertise 65
Competition within the Market-place 66
Competitor Ratio Analysis 66
Forecast .67

NAPTUMOMAB ESTAFENATOX  69
Mode of Action 69
Current Status 70
Proof of Concept/Clinical Data 70
Development Risks 70
Company Expertise 70
Competition within the Market-place 70
Competitor Ratio Analysis 71
Forecast .71

TIVOZANIB . 73
Mode of Action 73
Current Status 73
Proof of Concept/Clinical Data 73
Development Risks 74
Company Expertise 74
Competition within the Market-place 75
Competitor Ratio Analysis 75
Forecast .76

APPROVED . 77

ALDESLEUKIN  77
Mode of Action 77
Current Status 78
Proof of Concept/Clinical Data 78
Development Risks 78
Company Expertise 79
Competition within the Market-place 79
Competitor Ratio Analysis 80
Forecast .80

BEVACIZUMAB . 82
Mode of Action 82
Current Status 83
Proof of Concept/Clinical Data 85
Development Risks 88
Company Expertise 89
Competition within the Market-place 90
Competitor Ratio Analysis 92
Forecast .92
Clinical Trial Results .96

EVEROLIMUS . 100
Mode of Action 100
Current Status .101
Proof of Concept/Clinical Data 103
Development Risks .104
Company Expertise .105
Competition within the Market-place 105
Competitor Ratio Analysis .106
Forecast 106
Clinical Trial Results .107

HUMAN LYMPHOBLASTOID INTERFERON [IFN] ALPHA-N1 . 111

INTERFERON ALPHA-2A  112
Mode of Action 112
Current Status .112
Proof of Concept/Clinical Data 113
Development/Commercialisation Risks 113
Company Expertise .113
Competition within the Market-place 114
Competitor Ratio Analysis .114
Forecast 114

PAZOPANIB  116
Mode of Action 116
Current Status .116
Proof of Concept/Clinical Data 117
Development Risks .117
Company Expertise .118
Competition within the Market-place 118
Data Exclusivity .119
Patent Expiry 119
Competitor Ratio Analysis .119
Forecast 119
Clinical Trial Results .121

SORAFENIB  122
Mode of Action 122
Current Status .123
Proof of Concept/Clinical Data 124
Development Risks .125
Company Expertise .125
Competition within the Market-place 126
Data Exclusivity .126
Patent Expiry 126
Competitor Ratio Analysis .127
Forecast 127
Clinical Trial Results .130

SUNITINIB MALATE 131
Mode of Action 131
Current Status .132
Proof of Concept/Clinical Data 132
Development Risks .133
Company Expertise .134
Competition within the Market-place 135
Data Exclusivity .136
Patent Expiry 136
Generic Competition .136
Competitor Ratio Analysis .136
Forecast 137
Clinical Trial Results .139

TEMSIROLIMUS 142
Mode of Action 142
Current Status .144
Proof of Concept/Clinical Data 144
Development Risks .145
Company Expertise .145
Competition within the Market-place 145
Data Exclusivity .147
Patent Expiry 147
Competitor Ratio Analysis .147
Forecast 147
Clinical Trial Results .149

VITESPEN  151
Mode of Action 151
Current Status .151
Proof of Concept/Clinical Data 152
Development Risks .152
Company Expertise .153
Competition within the Market-place 153
Competitor Ratio Analysis .153
Forecast 154
ABT-510 . 156
Mode of Action 156
Current Status .156
Clinical Trial Results .156
ABT-751 . 157
Mode of Action 157
Current Status .157

ARCHEXIN . 158
Mode of Action 158
Current Status .158
Proof of Concept/Clinical Data 159
Development/Commercialisation Risks 159
Company Expertise .159
Competition within the Market-place 159
Competitor Ratio Analysis .159
IMO-2055  160
Mode of Action 160
Current Status .160
Proof of Concept/Clinical Data 160
Company Expertise .161
Clinical Trial Results .161
SAR109659 . 162
Mode of Action 162
Current Status .162
Proof of Concept/Clinical Data 162
Development Risks .163
Company Expertise .163
Competition within the Market-place 163
Competitor Ratio Analysis .164
Clinical Trial Results .164

METHODOLOGY  166